Highlights
- Zydus Lifesciences shares gained more than 1.5% during Friday's morning session on the NSE.
- The pharmaceutical company reported consolidated Q4 FY26 net profit of Rs 1,341 crore.
- The stock traded close to its 52-week high while outperforming its benchmark across multiple periods.
Zydus Lifesciences Ltd. (NSE:ZYDUSLIFE) traded higher during the morning session on July 3, 2026, with the stock rising 1.65% to Rs 1,118.00 at 11:22 AM IST. The stock opened at Rs 1,105.00 against the previous closing price of Rs 1,099.80. During the session, it touched an intraday high of Rs 1,122.80 and a low of Rs 1,104.10. The volume-weighted average price (VWAP) stood at Rs 1,114.53, indicating steady trading throughout the session.
Trading Activity Remains Steady
The stock witnessed active trading on the National Stock Exchange, with approximately 2.55 lakh shares changing hands by 11:22 AM IST. The traded value stood at around Rs 28.37 crore. The order book reflected higher selling interest than buying interest during the session, with sell-side orders accounting for 58.36% of the visible quantity compared with 41.64% on the buy side. The impact cost remained at 0.03, indicating adequate liquidity in the counter.
Stock Trades Close to 52-Week High
Zydus Lifesciences continued to trade close to its 52-week high of Rs 1,128.50 recorded on June 30, 2026. The stock remained well above its 52-week low of Rs 835.50 touched on April 2, 2026. At the prevailing market price, the company's market capitalisation stood at approximately Rs 1.12 lakh crore, while its free-float market capitalisation was around Rs 27,890.23 crore.
Share Performance Across Different Time Frames
Zydus Lifesciences has delivered positive returns across all measured periods. The stock has gained 1.46% over the past week and 3.80% during the last month. On a year-to-date basis, it has advanced 22.12%, while the one-year return stands at 11.82%. Over the past three years, the stock has generated an absolute return of 93.21%, while its five-year return stands at 74.79%. The company is a constituent of the Nifty Next 50 index and operates in the pharmaceuticals industry.
Q4 FY26 Financial Performance
For the quarter ended March 31, 2026, Zydus Lifesciences reported unaudited consolidated total income of Rs 7,72,120 lakh. Consolidated profit before tax stood at Rs 1,65,970 lakh, while consolidated net profit came in at Rs 1,34,100 lakh. Earnings per share (EPS) for the quarter were reported at Rs 12.65.
On a standalone basis, the company reported unaudited total income of Rs 4,23,600 lakh. Profit before tax stood at Rs 2,11,100 lakh, while net profit was Rs 1,72,200 lakh. Standalone earnings per share came in at Rs 17.11. The financial results were announced on May 19, 2026.
Valuation and Market Metrics
Zydus Lifesciences traded at a price-to-earnings (P/E) ratio of 22.02, while its adjusted P/E stood at 20.52. The stock recorded daily volatility of 1.49% and annualised volatility of 28.47%. Deliverable trades accounted for 61.06% of the total traded quantity during the session, indicating that a majority of traded shares resulted in delivery-based transactions.
Key Risks
- Regulatory approvals may affect product launches.
- Pricing pressure could influence pharmaceutical margins.
- Currency movements may impact export earnings.
- Market volatility can affect healthcare sector valuations.
Summary
Zydus Lifesciences shares gained 1.65% during the morning session on July 3, 2026, trading close to their 52-week high on the National Stock Exchange. The stock has delivered positive returns across all major time frames while recording active trading. The company's latest quarterly results reported consolidated net profit of Rs 1,341 crore and earnings per share of Rs 12.65.
FAQs
Q: What was Zydus Lifesciences' share price on July 3, 2026?
A: Zydus Lifesciences traded at Rs 1,118.00 at 11:22 AM IST, up 1.65% from the previous closing price.
Q: What was Zydus Lifesciences' consolidated net profit in Q4 FY26?
A: The company reported consolidated net profit of Rs 1,341 crore for the quarter ended March 31, 2026.
Q: What are Zydus Lifesciences' 52-week high and low share prices?
A: The stock's 52-week high is Rs 1,128.50, while its 52-week low is Rs 835.50.